{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:54:57Z","timestamp":1793656497101,"version":"4.5.1"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,2]],"date-time":"2027-01-02T00:00:00Z","timestamp":1798848000000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022939","name":"Zell Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022939","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U54 DK144863"],"award-info":[{"award-number":["U54 DK144863"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01 DK142878"],"award-info":[{"award-number":["R01 DK142878"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejim.2025.106557","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T03:31:01Z","timestamp":1761190261000},"page":"106557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Contemporary management of advanced chronic kidney disease: An evidence-based review"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4937-8357","authenticated-orcid":false,"given":"Lyle W.","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cene","family":"Ovincy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levon","family":"Souvalian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LaTonya J.","family":"Hickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3949-5720","authenticated-orcid":false,"given":"Fouad T.","family":"Chebib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2025.106557_bib0001","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"2024 Clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2025.106557_bib0002","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global burden of disease study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2025.106557_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100060","article-title":"Innovative therapeutics for renoprotection: where we are","volume":"77","author":"Cortinovis","year":"2025","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.ejim.2025.106557_bib0004","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American diabetes association (ADA) and Kidney disease: improving global outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2025.106557_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review","volume":"8","author":"Fonseca-Correa","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094416","article-title":"Multi-organ protective effects of sodium glucose cotransporter 2 inhibitors","volume":"22","author":"Yanai","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejim.2025.106557_bib0007","article-title":"Chronic kidney disease and risk management: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2025.106557_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108330","article-title":"Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease","volume":"242","author":"Solomon","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ejim.2025.106557_bib0009","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0010","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2215\/CJN.14901219","article-title":"Empagliflozin and cardiovascular and kidney outcomes across KDIGO risk categories: post hoc analysis of a randomized, double-blind, placebo-controlled, multinational trial","volume":"15","author":"Levin","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2025.106557_bib0011","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0012","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0013","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0014","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of Empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2025.106557_bib0016","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial","volume":"140","author":"Nassif","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2025.106557_bib0017","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.jacc.2024.06.036","article-title":"Effects of Sotagliflozin on health status in patients with worsening heart failure: results from SOLOIST-WHF","volume":"84","author":"Bhatt","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2025.106557_bib0018","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jchf.2023.05.026","article-title":"Effect of Sotagliflozin on early mortality and heart failure-related events: A post hoc analysis of SOLOIST-WHF","volume":"11","author":"Pitt","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.ejim.2025.106557_bib0019","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S2213-8587(24)00362-0","article-title":"Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial","volume":"13","author":"Aggarwal","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ejim.2025.106557_bib0020","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0021","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2025.106557_bib0022","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1681\/ASN.2019111168","article-title":"Renal, cardiovascular, and safety outcomes of Canagliflozin by baseline kidney function: A secondary analysis of the CREDENCE randomized trial","volume":"31","author":"Jardine","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2025.106557_bib0023","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ejim.2025.106557_bib0024","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0025","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2409183","article-title":"Long-term effects of Empagliflozin in patients with chronic Kidney disease","volume":"392","author":"Herrington","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0026","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1111\/dom.15789","article-title":"Barriers to early diagnosis of chronic kidney disease and use of sodium-glucose cotransporter-2 inhibitors for renal protection: A comprehensive review and call to action","volume":"26","author":"Czupryniak","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ejim.2025.106557_bib0027","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"A consensus report by the american diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2025.106557_bib0028","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"A consensus report by the american diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2025.106557_bib0029","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.ejim.2025.106557_bib0030","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0031","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ejim.2025.106557_bib0032","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0033","series-title":"FDA Approves New Indication For Ozempic To Treat Chronic Kidney Disease In Adults With Type 2 Diabetes","year":"2025"},{"key":"10.1016\/j.ejim.2025.106557_bib0034","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","article-title":"Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial","volume":"31","author":"Apperloo","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0035","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.101773","article-title":"Eligibility and preventable cardiovascular, Diabetes, and kidney outcomes from Semaglutide in the SELECT trial","volume":"4","author":"Yan","year":"2025","journal-title":"JACC Adv"},{"key":"10.1016\/j.ejim.2025.106557_bib0037","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/j.ajkd.2022.04.016","article-title":"Mineralocorticoid receptor activation, and CKD: A review of evolving treatment paradigms","volume":"80","author":"Epstein","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejim.2025.106557_bib0038","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2025.106557_bib0039","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2025.106557_bib0040","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1093\/eurheartj\/ehac299","article-title":"Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"43","author":"Pandey","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2025.106557_bib0041","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/13543784.2021.2002844","article-title":"Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics","volume":"30","author":"Barrera-Chimal","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ejim.2025.106557_bib0042","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s40265-021-01599-7","article-title":"Finerenone: first approval","volume":"81","author":"Frampton","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejim.2025.106557_bib0043","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0044","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0045","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2025.106557_bib0046","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jacc.2024.09.023","article-title":"Effect of finerenone on the KCCQ in patients with HFmrEF\/HFpEF: A prespecified analysis of FINEARTS-HF","volume":"85","author":"Yang","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2025.106557_bib0047","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with Empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0048","article-title":"Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes: A systematic review incorporating an indirect comparisons meta-analysis","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ejim.2025.106557_bib0049","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/ndt\/gfs388","article-title":"Aldosterone synthase inhibition in humans","volume":"28","author":"Azizi","year":"2013","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.ejim.2025.106557_bib0050","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2507109","article-title":"Efficacy and safety of Baxdrostat in uncontrolled and resistant hypertension","author":"Flack","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0051","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1001\/jama.2025.0310","article-title":"Autosomal dominant polycystic Kidney disease: a review","volume":"333","author":"Chebib","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2025.106557_bib0052","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.kint.2024.07.010","article-title":"KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary","volume":"107","author":"Torres","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2025.106557_bib0053","article-title":"Autosomal dominant polycystic kidney disease: an overview of recent genetic and clinical advances","volume":"47","author":"Borghol","year":"2025","journal-title":"Ren Fail"},{"key":"10.1016\/j.ejim.2025.106557_bib0054","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrneph.2015.39","article-title":"Vasopressin and disruption of calcium signalling in polycystic kidney disease","volume":"11","author":"Chebib","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ejim.2025.106557_bib0055","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat","volume":"16","author":"Wang","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2025.106557_bib0056","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0057","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0058","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial","volume":"33","author":"Torres","year":"2018","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.ejim.2025.106557_bib0059","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0060","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2215\/CJN.01520218","article-title":"Long-term administration of Tolvaptan in autosomal dominant polycystic kidney disease","volume":"13","author":"Edwards","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2025.106557_bib0061","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.ekir.2021.05.037","article-title":"Tolvaptan in ADPKD patients with very low kidney function","volume":"6","author":"Torres","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ejim.2025.106557_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100639","article-title":"Tolvaptan and kidney function decline in older individuals with autosomal dominant polycystic kidney disease: A pooled analysis of randomized clinical trials and observational studies","volume":"5","author":"Chebib","year":"2023","journal-title":"Kidney Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0063","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s40265-015-0475-x","article-title":"Tolvaptan: A review in autosomal dominant polycystic kidney disease","volume":"75","author":"Blair","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.ejim.2025.106557_bib0064","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1681\/ASN.2018060590","article-title":"A practical guide for treatment of rapidly progressive ADPKD with Tolvaptan","volume":"29","author":"Chebib","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2025.106557_bib0065","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1038\/s41467-022-32543-2","article-title":"PKD1 and PKD2 mRNA cis-inhibition drives polycystic kidney disease progression","volume":"13","author":"Lakhia","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejim.2025.106557_bib0066","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1038\/s41467-019-11918-y","article-title":"Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease","volume":"10","author":"Lee","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejim.2025.106557_bib0067","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.135700","article-title":"Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis","volume":"5","author":"Kashyap","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejim.2025.106557_bib0068","series-title":"A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)","year":"2025"},{"key":"10.1016\/j.ejim.2025.106557_bib0069","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.omtm.2023.03.016","article-title":"Modeling Pkd1 gene-targeted strategies for correction of polycystic kidney disease","volume":"29","author":"Kurbegovic","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.ejim.2025.106557_bib0070","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/sctm.19-0419","article-title":"A systematic review and meta-analysis of cell-based interventions in experimental diabetic kidney disease","volume":"10","author":"Hickson","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0071","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jcyt.2025.01.005","article-title":"ISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells","volume":"27","author":"Blanc","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ejim.2025.106557_bib0072","doi-asserted-by":"crossref","first-page":"542","DOI":"10.34067\/KID.0005692020","article-title":"Progress toward the clinical application of mesenchymal stromal cells and other disease-modulating regenerative therapies: examples from the field of nephrology","volume":"2","author":"Hickson","year":"2021","journal-title":"Kidney360"},{"key":"10.1016\/j.ejim.2025.106557_bib0073","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1681\/ASN.2017070781","article-title":"Clinical translation of mesenchymal stromal cell therapies in nephrology","volume":"29","author":"Perico","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2025.106557_bib0074","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2337\/db19-1268","article-title":"Diabetic kidney disease alters the transcriptome and function of Human adipose-derived mesenchymal stromal cells but maintains immunomodulatory and paracrine activities important for renal repair","volume":"70","author":"Hickson","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2025.106557_bib0075","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.kint.2015.11.023","article-title":"Challenges and opportunities for stem cell therapy in patients with chronic kidney disease","volume":"89","author":"Hickson","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2025.106557_bib0076","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1634\/stemcells.2007-0795","article-title":"Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice","volume":"26","author":"Morigi","year":"2008","journal-title":"Stem Cells"},{"key":"10.1016\/j.ejim.2025.106557_bib0077","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3109\/0886022X.2010.494803","article-title":"Repeated administration of bone marrow-derived mesenchymal stem cells improved the protective effects on a remnant kidney model","volume":"32","author":"Lee","year":"2010","journal-title":"Ren Fail"},{"key":"10.1016\/j.ejim.2025.106557_bib0078","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/ard.2009.123463","article-title":"Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study","volume":"69","author":"Liang","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2025.106557_bib0079","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jcyt.2018.02.368","article-title":"Bone marrow-mesenchymal stromal cell infusion in patients with chronic kidney disease: A safety study with 18 months of follow-up","volume":"20","author":"Makhlough","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ejim.2025.106557_bib0080","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1681\/ASN.2017020151","article-title":"Autologous mesenchymal stem cells increase cortical perfusion in renovascular disease","volume":"28","author":"Saad","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2025.106557_bib0081","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.kint.2019.11.022","article-title":"In a phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure","volume":"97","author":"Abumoawad","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2025.106557_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.ekir.2025.07.042","article-title":"Intraarterial autologous mesenchymal stem cell therapy for diabetic kidney disease","author":"Alatta","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ejim.2025.106557_bib0083","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1681\/ASN.2016101150","article-title":"Allogeneic mesenchymal stem cells for treatment of AKI after cardiac surgery","volume":"29","author":"Swaminathan","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2025.106557_bib0084","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1681\/ASN.0000000000000189","article-title":"Safety and preliminary efficacy of mesenchymal stromal cell (ORBCEL-M) therapy in diabetic kidney disease: A randomized clinical trial (NEPHSTROM)","volume":"34","author":"Perico","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2025.106557_bib0085","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ebiom.2016.09.011","article-title":"Allogeneic mesenchymal precursor cells (MPC) in diabetic nephropathy: A randomized, placebo-controlled, dose escalation study","volume":"12","author":"Packham","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejim.2025.106557_bib0086","doi-asserted-by":"crossref","DOI":"10.1155\/sci\/8658246","article-title":"Narrative review of mesenchymal stem cell therapy in renal diseases: mechanisms, clinical applications, and future directions","volume":"2024","author":"Wang","year":"2024","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.ejim.2025.106557_bib0087","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13287-023-03269-9","article-title":"Diabetic kidney disease induces transcriptome alterations associated with angiogenesis activity in human mesenchymal stromal cells","volume":"14","author":"Bian","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.ejim.2025.106557_bib0088","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000537942","article-title":"Rilparencel (Renal Autologous Cell Therapy-REACT(R)) for chronic kidney disease and type 1 and type 2 diabetes: phase 2 trial design evaluating bilateral kidney dosing and redosing triggers","volume":"55","author":"Stavas","year":"2024","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ejim.2025.106557_bib0089","unstructured":"ProKidney I. ProKidney reports statistically and clinically significant topline results for the phase 2 REGEN-007 trial evaluating Rilparencel in patients with chronic kidney disease and diabetes. 2025."},{"key":"10.1016\/j.ejim.2025.106557_bib0090","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1681\/ASN.0000000754","article-title":"Fortifying the diabetic kidney disease treatment armamentarium: multitarget senotherapeutic and regenerative strategies","volume":"36","author":"Patel","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2025.106557_bib0091","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000005372","article-title":"International Xenotransplantation Association (IXA) position paper on Kidney Xenotransplantation","author":"Meier","year":"2025","journal-title":"Transplantation"},{"key":"10.1016\/j.ejim.2025.106557_bib0092","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/xen.12219","article-title":"The pathobiology of pig-to-primate xenotransplantation: a historical review","volume":"23","author":"Cooper","year":"2016","journal-title":"Xenotransplantation"},{"key":"10.1016\/j.ejim.2025.106557_bib0093","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00041.2023","article-title":"Physiological basis for xenotransplantation from genetically modified pigs to humans","volume":"104","author":"Peterson","year":"2024","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ejim.2025.106557_bib0094","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1056\/NEJMra1913421","article-title":"Immune and genome engineering as the future of transplantable tissue","volume":"385","author":"Elisseeff","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0095","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa2120238","article-title":"Results of two cases of pig-to-Human kidney xenotransplantation","volume":"386","author":"Montgomery","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0096","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa2412747","article-title":"Xenotransplantation of a porcine kidney for end-stage kidney disease","volume":"392","author":"Kawai","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0097","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ejim.2025.106557_bib0098","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2025.106557_bib0099","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2025.106557_bib0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing Esaxerenone (CS-3150) and Eplerenone in patients with essential hypertension (ESAX-HTN Study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2025.106557_bib0101","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2025.106557_bib0102","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100935","article-title":"Tolvaptan and autosomal dominant polycystic kidney disease progression in individuals aged 18-35 years: a pooled database analysis","volume":"7","author":"Chebib","year":"2025","journal-title":"Kidney Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525004340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525004340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:14:10Z","timestamp":1773911650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620525004340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":102,"alternative-id":["S0953620525004340"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2025.106557","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary management of advanced chronic kidney disease: An evidence-based review","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2025.106557","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106557"}}